We wish to inform you that the Board of Directors at its meeting held today i.e., May 14, 2026, has inter-alia approved the Audited Financial Results for the quarter and year ended March ....
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alivus Life Sciences reported strong full-year results with revenue from operations growing 6.9% to Rs 25,518.32 million in FY26 from Rs 23,868.84 million in FY25. Profit after tax increased 16.2% to Rs 5,644.83 million from Rs 4,856.27 million. EPS for the year stood at Rs 45.99. The Board recommended a final dividend of Rs 5 per share (250% on face value of Rs 2). The statutory auditor Walker Chandiok & Co LLP issued an unmodified (clean) opinion on the financial results. An exceptional item of Rs 256.57 million was recognized due to the implementation of New Labour Codes (gratuity Rs 170.02 million and compensated absences Rs 86.55 million). Cash and cash equivalents declined significantly from Rs 710.62 million to Rs 19.82 million as the company invested heavily in capital work-in-progress and mutual funds.
Positive signals for shareholders with consistent revenue and profit growth, clean audit opinion, and attractive dividend payout. The sharp decline in cash reserves warrants monitoring as it suggests heavy investment activity.